Evaluation of platelet-rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial

J Cosmet Dermatol. 2023 Jul;22(7):1995-2002. doi: 10.1111/jocd.15825. Epub 2023 May 17.

Abstract

Background: Platelet-rich plasma plus basic fibroblast growth factor (PRPF) has been confirmed to be a safe and valuable therapy for androgenetic alopecia (AGA). However, the efficacy of PRPF combined with minoxidil treatment remains unknown.

Objective: To assess the efficacy of combined PRPF and minoxidil treatment for AGA.

Methods: In this prospective, randomized controlled trial, 75 patients with AGA were randomly divided into three groups and were administered the following treatments: Group 1, direct intradermal PRPF injection; Group 2, topical minoxidil 5% twice daily; and Group 3, PRPF injection combined with minoxidil. The PRPF injection was performed three times, 1 month apart. Hair growth parameters were evaluated using a trichoscope until the sixth month of the study. Patient satisfaction and side effects were recorded during the follow-up.

Results: All patients showed improvements (p < 0.05) in hair count, terminal hair, and decrease in telogen hair ratio after treatment. The efficacy of PRPF complex therapy revealed significant improvements (p < 0.05) in hair count, terminal hair and growth rate, compared with monotherapy.

Limitations: Small sample size, short follow-up time and lack of quantification of GFs in PRPF.

Conclusion: The effect of complex therapy exceed both the effects of PRPF monotherapy and minoxidil treatment, which can be a beneficial AGA treatment strategy.

Keywords: androgenetic alopecia; basic fibroblast growth factor; complex therapy; minoxidil; platelet-rich plasma.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Alopecia / diagnosis
  • Alopecia / drug therapy
  • Fibroblast Growth Factor 2 / therapeutic use
  • Humans
  • Minoxidil* / adverse effects
  • Platelet-Rich Plasma*
  • Prospective Studies
  • Treatment Outcome

Substances

  • Minoxidil
  • Fibroblast Growth Factor 2